Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial

Aims Both low and high body mass index (BMI) are associated with poor heart failure outcomes. Whether BMI modifies benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) requires further investigation. Methods and results Using EMPERO...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2024-04, Vol.26 (4), p.900-909
Main Authors: Sattar, Naveed, Butler, Javed, Lee, Matthew M.Y., Harrington, Josephine, Sharma, Abhinav, Zannad, Faiez, Filippatos, Gerasimos, Verma, Subodh, Januzzi, James L., Ferreira, João Pedro, Pocock, Stuart J., Pfarr, Egon, Ofstad, Anne P., Brueckmann, Martina, Packer, Milton, Anker, Stefan D.
Format: Article
Language:English
Subjects:
Aged
Benzhydryl Compounds - therapeutic use
Body Mass Index
Female
Glomerular Filtration Rate
Glucosides - therapeutic use
Heart Failure - drug therapy
Heart Failure - mortality
Heart Failure - physiopathology
HFpEF
Hospitalization - statistics & numerical data
Humans
Kidney disease
Life Sciences
Male
Middle Aged
SGLT2 inhibitor
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Stroke Volume - physiology
Treatment Outcome
Weight
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Both low and high body mass index (BMI) are associated with poor heart failure outcomes. Whether BMI modifies benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) requires further investigation. Methods and results Using EMPEROR‐Preserved data, the effects of empagliflozin versus placebo on the risks for the primary outcome (hospitalization for heart failure [HHF] or cardiovascular [CV] death), change in estimated glomerular filtration rate (eGFR) slopes, change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ‐CSS), and secondary outcomes across baseline BMI categories (
ISSN:1388-9842
1879-0844
1879-0844
DOI:10.1002/ejhf.3221